SIMCERE PHARMA

2096
10.5500.28% ( -0.030 )
Delay Closed: Nov 16, 16:08:11

Overview

SIMCERE PHARMA (2096)

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to d...

Open
10.490
High
10.630
Low
10.420
Prev. Close
10.580
Volume
3.08M
Turnover
32.42M
Avg Price
10.535
Bid/Ask Ratio
-75.00%
Amplitude
1.98%
52wk High
14.173
Volume Ratio
0.44
Turnover Ratio
0.12%
52wk Low
9.070
HK Mkt Cap
27.09B
Market CapHKD
27.09B
P/ETTM
14.97
P/EDynamic
14.20
P/EStatic
--
EPSTTM
0.705
EPSDynamic
0.743
EPSStatic
--
BVPS
4.22
P/B
2.50
HK Shares
2.57B
Dividend YieldTTM
1.96%
DividendTTM
0.2069
Shares
2.57B
Min lot size
1,000
Currency
HKD

SIMCERE PHARMA Analyst Rating

View more

Forecast & Rating

Oct 27, 2026
Price forecast
HK$19.5084.84%
Forecast & RatingStrong buy
5analysts
  • Strong buy80.00%
  • Buy20.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 4

    Simcere Pharma rose 4.81% to HK$10.67 after a low open, climbing from HK$10.17 at 09:32 BJ to an intraday HK$10.81 at 15:11 BJ, with 8.07 million shares and HK$84.7 million traded, as the deal to grant LinkHealth exclusive promotion rights for zepruxitinib in dermatology coincided with the buyback of 528,000 shares for HK$5.3634 million on November 3 and shareholder Peng Suqin adding 200,000 shares at HK$10.28; strength across Hong Kong innovative-drug names added support. Fundamentals show Q2 2026 revenue of HK$2.645 billion, up 34.67% year on year, net profit of HK$478.6 million up 45.34%, operating income of HK$601.8 million up 54.29%, a 18.09% net margin and 17.59% ROE, against a 15.17x PE and 2.53x PB. The stock sits above its MA20 of HK$10.65 but is still down 9.58% year to date, 25.8% below the 52-week high of HK$14.38 and under the MA60 of HK$11.294, leaving the move within a recovery range.

  2. Oct, 27

    Simcere Pharma spiked then faded: after touching HK$10.550 at 09:36 BJ it drifted lower through the afternoon to close at HK$10.150, about 3.4% below the prior close of HK$10.510 — at odds with its steady buybacks, including 1.102 million shares for HK$11.67 million on October 26 and roughly HK$15.43 million on October 22. Q2 2026 revenue rose 34.67% yoy to HK$2.645 billion, net profit 45.34% to HK$478.6 million and EPS 37.15% to HK$0.1848, with PE at 13.69. UBS reiterated it as a top pick on October 22, innovative-drug names firmed during ESMO, and Roche's licensing of SIM0660 was read as validating the TCE platform. It is still down 18.26% YTD, 32.93% below the 52-week high of HK$14.38 and under MA20 (11.001) and MA60 (11.489), though turnover of about HK$914 million showed no heavy selling.

  3. Sep, 21

    Simcere Pharmaceutical opened lower then rallied in the morning session, last trading at HK$11.76 by 10:22 BJ, up 5.28%, driven by China‘s approval of its RSV prevention antibody Yingmule for infants and its unit Zaiming’s exclusive global license agreement with Roche for SIM0660 in a deal worth up to $1.53 billion. Q2 2026 revenue hit HK$2.64 billion (+34.72% YoY) and net profit reached HK$478 million (+45.39% YoY), yet the stock still trades 18.22% below its 52-week high of HK$14.38 and below its 60-day MA of HK$11.952, while the YTD change is a marginal -0.34%, with earnings improvement and the major licensing deal providing support.

  4. Sep, 18

    Simcere Pharmaceutical Group opened higher but closed lower today, peaking at HKD 11.49 in the morning session before retreating to HKD 11.15 by the afternoon close, trading 22.32% below its 52-week high of HKD 14.38 and down 5.34% YTD. Despite strong Q2 results with revenue up 34.72% YoY to HKD 2.64 billion, net profit surging 45.39% YoY to HKD 478 million, and EPS of HKD 0.1847 growing 37.2% YoY, the stock remains below both its 20-day (HKD 11.408) and 60-day (HKD 11.91) moving averages, suggesting market caution on the near-term catalyst from the recently announced potential USD 1.53 billion licensing deal with Roche. Nonetheless, UBS has named Simcere a top pick among Chinese pharma stocks, and ongoing share buybacks provide some support.

  5. Sep, 2

    Simcere Pharmaceutical opened higher and rallied, reaching HKD 11.55 by 09:37 BJ, up 5.10% with 1.774 million shares traded (turnover ~HKD 20.28 million). The intraday range was HKD 11.26-11.55. The catalyst is Roche's licensing agreement with subsidiary Simcere Zaiming for SIM0660, worth up to USD 1.53 billion. Q2 revenue hit HKD 2.64 billion (+34.7% YoY), net profit HKD 478 million (+45.4% YoY), operating profit up 54.3% to HKD 601 million, with EPS of HKD 0.1847 (+37.2% YoY). The stock trades 23.4% below its 52-week high of HKD 15.08 but 27.3% above its low of HKD 9.07, sitting on the MA60 (HKD 11.55) yet below the MA20 (HKD 11.92) and down 2.1% YTD, suggesting near-term resistance.

News

Bullish vs. Bearish — Last 3 Months

5.3k followers · 0 opinions
▲Bullish50%
50%Bearish▼